Investors Have a Unique Chance to Guide Soleno Therapeutics Securities Lawsuit

Investors Urged to Join Soleno Therapeutics Class Action

Recent developments surrounding Soleno Therapeutics, Inc. (NASDAQ: SLNO) have offered investors a potentially significant window to seek justice following a suspected securities fraud. Rosen Law Firm, a global legal firm specializing in investor rights, has called upon those who purchased Soleno's common stock between March 26, 2025, and November 4, 2025, to consider joining a class action lawsuit. The deadline to act is May 5, 2026, an important date that all potential class members must be aware of.

Purchasers during this specific period might be eligible for compensation without the burden of any out-of-pocket costs or fees, thanks to a contingency fee arrangement that the firm has established. This could present a vital opportunity for those hurt by the alleged misrepresentation of critical information.

Key Information on the Lawsuit

The class action lawsuit highlights several claims against Soleno and its executives, alleging they provided misleading information regarding the safety of the company's diazoxide choline extended-release tablets (DCCR). According to the suit, essential evidence indicating safety concerns was not disclosed. This included revelations about potential risks related to fluid retention among clinical trial participants using DCCR to manage hyperphagia in individuals with Prader-Willi syndrome.

Consequently, these undisclosed safety risks allegedly placed DCCR's commercial viability in jeopardy. As the true nature of these risks emerged, investors faced considerable financial damages, leading to the current legal actions pushed forward by Rosen Law Firm. The firm's commitment to investor advocacy has been demonstrated through previous high-stake settlements and a prominent position in securities class action litigation.

Taking Next Steps

For those looking to take part in the Soleno Therapeutics class action, there are clear channels to get involved. Interested investors can visit the Rosen Law Firm's dedicated webpage or get in touch directly with attorney Phillip Kim. Participation in this class action does not require retaining the law firm as counsel immediately, as no class has yet been certified. Investors can either choose their own representation or remain passive as part of the class until further proceedings develop.

Essentially, this initiative not only illustrates the complexities of the financial landscape surrounding emerging pharmaceutical companies but also underscores the vital role investors play in demanding accountability from corporate entities. By taking action, investors can position themselves at the forefront of this critical legal process, potentially impacting outcomes that extend beyond individual recovery to broader corporate accountability.

About Rosen Law Firm

The Rosen Law Firm has garnered a strong reputation in the realm of class action lawsuits. Founded with a mission to protect investor rights, the firm has directed its efforts towards high-stakes securities litigation, successfully securing significant settlements for investors even in challenging environments. With rankings that place them among the best in the industry, Rosen stands out for their rigorous approach and proven results, including record recoveries that emphasize financial justice for aggrieved investors.

As the May deadline approaches, those affected by Soleno Therapeutics' alleged missteps are advised to evaluate their positions swiftly. The potential benefits of participating in this class action could be monumental, advocating not just for personal recovery, but reinforcing the importance of transparency and integrity in the corporate sphere.

For further inquiries or details regarding the class action, contact:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel (212) 686-1060
Toll Free (866) 767-3653
Email: [email protected]
Website: www.rosenlegal.com